ly3209590
Small moleculeexperimental
Clinical trial activity
19 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Dec 20, 2016 (NCT02942914)
Timeline
Indications
Mechanism of action
- Insulin receptorAGONIST
INSR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3209590
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06362265 | Phase 1 | Oct 10, 2024 | Eli Lilly |
| NCT06169982 | Phase 1 | Dec 9, 2023 | Eli Lilly |
| NCT05914688 | Phase 1 | Jun 26, 2023 | Eli Lilly |
| NCT05662332 | Phase 3 | Jan 16, 2023 | Eli Lilly |
| NCT05596747 | Phase 1 | Nov 30, 2022 | Eli Lilly |
| NCT05615532 | Phase 1 | Nov 11, 2022 | Eli Lilly |
| NCT05463744 | Phase 3 | Aug 12, 2022 | Eli Lilly |
| NCT05462756 | Phase 3 | Aug 11, 2022 | Eli Lilly |
| NCT05362058 | Phase 3 | Jun 3, 2022 | Eli Lilly |
| NCT05275400 | Phase 3 | Mar 8, 2022 | Eli Lilly |
| NCT04957914 | Phase 1 | Jul 14, 2021 | Eli Lilly |
| NCT04768842 | Phase 1 | Mar 3, 2021 | Eli Lilly |
| NCT04450407 | Phase 2 | Jul 6, 2020 | Eli Lilly |
| NCT04450394 | Phase 2 | Jul 1, 2020 | Eli Lilly |
| NCT04276428 | Phase 1 | Feb 28, 2020 | Eli Lilly |
| NCT03736785 | Phase 2 | Nov 15, 2018 | Eli Lilly |
| NCT03603704 | Phase 1 | Aug 17, 2018 | Eli Lilly |
| NCT03367377 | Phase 1 | Jan 3, 2018 | Eli Lilly |
| NCT02942914 | Phase 1 | Dec 20, 2016 | Eli Lilly |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 19 | 19 | 3 | 2016 |
1 organizations
Page 1 / 1